On June 30, 2022, the U.S. Food and Drug Administration (FDA) issued a warning letter to the Kratom Exchange, addressing significant concerns regarding the marketing practices
On June 30, 2022, the U.S. Food and Drug Administration (FDA) issued a warning letter to Klarity Kratom, a manufacturer of kratom products, highlighting significant regulatory
This warning letter addresses regulatory violations identified at Herbsens Botanicals during an FDA inspection. The inspection revealed significant issues regarding the labeling and marketing practices of
On May 18, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Front Range Kratom regarding the sale and distribution of kratom
On September 4, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Chillin Mix Kratom, addressing significant safety concerns associated with the
The FDA requires manufacturers or distributors of dietary ingredients introduced after October 15, 1994, to submit an NDIN at least 75 days prior to marketing the
The document is an NDI application letter related to a kratom product called Atomic K. Below you will also find the response from the FDA, indicating
This complaint, filed under case number 18-cv-2981, addresses allegations concerning the distribution and sale of bulk kratom products. The plaintiff contends that the defendants engaged in
This document presents a Complaint for Forfeiture filed by the United States Government against a company that fraudulently imported kratom powder without declaring it as kratom.
On June 30, 2022, the U.S. Food and Drug Administration (FDA) issued a warning letter to the Kratom Exchange, addressing significant concerns regarding the marketing practices
On June 30, 2022, the U.S. Food and Drug Administration (FDA) issued a warning letter to Klarity Kratom, a manufacturer of kratom products, highlighting significant regulatory
This warning letter addresses regulatory violations identified at Herbsens Botanicals during an FDA inspection. The inspection revealed significant issues regarding the labeling and marketing practices of
On May 18, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Front Range Kratom regarding the sale and distribution of kratom
On September 4, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Chillin Mix Kratom, addressing significant safety concerns associated with the
The FDA requires manufacturers or distributors of dietary ingredients introduced after October 15, 1994, to submit an NDIN at least 75 days prior to marketing the
The document is an NDI application letter related to a kratom product called Atomic K. Below you will also find the response from the FDA, indicating
This complaint, filed under case number 18-cv-2981, addresses allegations concerning the distribution and sale of bulk kratom products. The plaintiff contends that the defendants engaged in
This document presents a Complaint for Forfeiture filed by the United States Government against a company that fraudulently imported kratom powder without declaring it as kratom.
The Kratom Research Institute was established to create a trusted hub for kratom-related information. We are a non-partisan organization focused solely on delivering facts, studies, and news, without promoting or opposing the use of kratom. Our goal is to offer a clear, objective view of the current state of kratom research, regulations, and public discourse.
We understand that kratom is a topic of debate, and that’s why we take a balanced approach—presenting information from all sides so you can make informed decisions based on credible sources.
